M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - FRA:M12 - DE000A0STSQ8 - Common Stock
14.7 EUR
+0.3 (+2.08%)
We assign a fundamental rating of 7 out of 10 to M12. M12 was compared to 31 industry peers in the Health Care Providers & Services industry. M12 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. M12 has a decent growth rate and is not valued too expensively. With these ratings, M12 could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year M12 was profitable.
M12 had a positive operating cash flow in the past year.
M12 had positive earnings in each of the past 5 years.
Each year in the past 5 years M12 had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.73%, M12 belongs to the top of the industry, outperforming 96.77% of the companies in the same industry.
M12 has a Return On Equity of 15.03%. This is in the better half of the industry: M12 outperforms 77.42% of its industry peers.
M12 has a Return On Invested Capital of 13.44%. This is amongst the best in the industry. M12 outperforms 90.32% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for M12 is in line with the industry average of 6.75%.
The 3 year average ROIC (7.72%) for M12 is below the current ROIC(13.44%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROIC | 13.44% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
M12's Profit Margin of 5.00% is amongst the best of the industry. M12 outperforms 83.87% of its industry peers.
M12's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 8.52%, M12 is in the better half of the industry, outperforming 74.19% of the companies in the same industry.
M12's Operating Margin has declined in the last couple of years.
M12 has a Gross Margin of 19.29%. This is comparable to the rest of the industry: M12 outperforms 41.94% of its industry peers.
M12's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
M12 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, M12 has less shares outstanding
The number of shares outstanding for M12 has been increased compared to 5 years ago.
Compared to 1 year ago, M12 has a worse debt to assets ratio.
2.2 Solvency
M12 has an Altman-Z score of 5.25. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of M12 (5.25) is better than 100.00% of its industry peers.
M12 has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.70, M12 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
M12 has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, M12 belongs to the top of the industry, outperforming 96.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 5.25 |
ROIC/WACC1.86
WACC7.22%
2.3 Liquidity
M12 has a Current Ratio of 2.06. This indicates that M12 is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.06, M12 belongs to the top of the industry, outperforming 90.32% of the companies in the same industry.
M12 has a Quick Ratio of 1.35. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.35, M12 belongs to the top of the industry, outperforming 80.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
M12 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.36%, which is quite good.
M12 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.97% yearly.
M12 shows a small growth in Revenue. In the last year, the Revenue has grown by 6.52%.
Measured over the past years, M12 shows a very strong growth in Revenue. The Revenue has been growing by 34.44% on average per year.
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
3.2 Future
Based on estimates for the next years, M12 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.18% on average per year.
Based on estimates for the next years, M12 will show a quite strong growth in Revenue. The Revenue will grow by 8.24% on average per year.
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 15.64, M12 is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of M12 indicates a somewhat cheap valuation: M12 is cheaper than 67.74% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of M12 to the average of the S&P500 Index (25.89), we can say M12 is valued slightly cheaper.
The Price/Forward Earnings ratio is 12.67, which indicates a correct valuation of M12.
67.74% of the companies in the same industry are more expensive than M12, based on the Price/Forward Earnings ratio.
M12 is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.64 | ||
| Fwd PE | 12.67 |
4.2 Price Multiples
M12's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. M12 is cheaper than 80.65% of the companies in the same industry.
M12's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. M12 is cheaper than 70.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.81 | ||
| EV/EBITDA | 7.03 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of M12 may justify a higher PE ratio.
M12's earnings are expected to grow with 19.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.01
PEG (5Y)1.96
EPS Next 2Y14.78%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.47%, M12 has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 2.44, M12 pays a better dividend. On top of this M12 pays more dividend than 93.55% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, M12 pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.47% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.18%
FRA:M12 (11/14/2025, 7:00:00 PM)
14.7
+0.3 (+2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.8%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap288.71M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85
Price Target27.03 (83.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.47% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.64 | ||
| Fwd PE | 12.67 | ||
| P/S | 0.81 | ||
| P/FCF | 10.81 | ||
| P/OCF | 10.68 | ||
| P/B | 2.45 | ||
| P/tB | 10.51 | ||
| EV/EBITDA | 7.03 |
EPS(TTM)0.94
EY6.39%
EPS(NY)1.16
Fwd EY7.89%
FCF(TTM)1.36
FCFY9.25%
OCF(TTM)1.38
OCFY9.37%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)3.01
PEG (5Y)1.96
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROCE | 19.39% | ||
| ROIC | 13.44% | ||
| ROICexc | 18.99% | ||
| ROICexgc | 105.66% | ||
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% | ||
| FCFM | 7.52% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 21.13 | ||
| Cash Conversion | 76.34% | ||
| Profit Quality | 150.51% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.25 |
F-Score9
WACC7.22%
ROIC/WACC1.86
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year31.44%
EBIT Next 3Y27.49%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A
M1 KLINIKEN AG / M12.DE FAQ
Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?
ChartMill assigns a fundamental rating of 6 / 10 to M12.DE.
Can you provide the valuation status for M1 KLINIKEN AG?
ChartMill assigns a valuation rating of 5 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.
How profitable is M1 KLINIKEN AG (M12.DE) stock?
M1 KLINIKEN AG (M12.DE) has a profitability rating of 6 / 10.
What are the PE and PB ratios of M1 KLINIKEN AG (M12.DE) stock?
The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 15.64 and the Price/Book (PB) ratio is 2.45.